Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Kyowa Kirin is a Japanese drugmaker that develops and sells medicines for cancer, kidney disease, nervous-system disorders, and immune conditions.
Kyowa Kirin is a Japanese pharmaceutical company that makes prescription medicines, mostly for serious diseases. Its drugs treat several kinds of cancer, kidney disease, conditions of the brain and nerves, and immune system problems. It sells these medicines to hospitals and doctors, mostly in Japan, but also across the United States, Europe, and Asia.
The company's best-known product is Crysvita, a treatment for a rare inherited bone disease called X-linked hypophosphatemia, where the body leaks phosphate and bones become soft and weak. It's a big seller and a good example of Kyowa Kirin's strategy: hunt for rare diseases with few treatments, where a effective drug can command a high price and face little competition. The company also sells older mainstays in Japan, including drugs for high blood pressure and kidney-related problems, plus a cancer drug called Poteligeo. Kyowa Kirin has deep roots in fermentation science. It started life making chemicals and amino acids through fermentation — the same brewing-style process used for beer and soy sauce — and that know-how eventually led it into making medicines. Its parent lineage traces back to a 1949 Japanese company, and it has long been associated with the Kirin brewing family. Today it's a fully fledged biopharma firm rather than a chemical maker.
Its main challenge is the same one facing every drug company: patents expire, and when they do, cheap copycat versions of a drug can wipe out much of its sales. So Kyowa Kirin must keep finding new medicines to replace the old ones. It spends heavily on research and development, and it has been expanding in the United States and Europe to reduce its reliance on the Japanese market, where prices are under government pressure. It faces competition from much larger global drugmakers, so staying nimble and focused on niche diseases is central to its plan.
Saved answer · last researched 15 Nov 2026